AU2001282717A1 - Cancer treatment by combination therapy - Google Patents
Cancer treatment by combination therapyInfo
- Publication number
- AU2001282717A1 AU2001282717A1 AU2001282717A AU8271701A AU2001282717A1 AU 2001282717 A1 AU2001282717 A1 AU 2001282717A1 AU 2001282717 A AU2001282717 A AU 2001282717A AU 8271701 A AU8271701 A AU 8271701A AU 2001282717 A1 AU2001282717 A1 AU 2001282717A1
- Authority
- AU
- Australia
- Prior art keywords
- combination therapy
- cancer treatment
- cancer
- treatment
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ506060 | 2000-07-28 | ||
| NZ50606000 | 2000-07-28 | ||
| PCT/NZ2001/000154 WO2002009700A1 (en) | 2000-07-28 | 2001-07-27 | Cancer treatment by combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001282717A1 true AU2001282717A1 (en) | 2002-02-13 |
Family
ID=19928021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001282717A Abandoned AU2001282717A1 (en) | 2000-07-28 | 2001-07-27 | Cancer treatment by combination therapy |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7510830B2 (en) |
| EP (1) | EP1311262A4 (en) |
| JP (1) | JP2004505047A (en) |
| AU (1) | AU2001282717A1 (en) |
| WO (1) | WO2002009700A1 (en) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE324888T1 (en) * | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | CANCER THERAPY |
| JP2001247459A (en) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | Cancer combination therapy |
| EP1311262A4 (en) | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | CANCER THERAPY THROUGH COMBINATION THERAPY |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| US6916831B2 (en) * | 2003-02-24 | 2005-07-12 | The University Of North Carolina At Chapel Hill | Flavone acetic acid analogs and methods of use thereof |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
| WO2007023302A1 (en) * | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
| CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
| US10369222B2 (en) | 2012-01-18 | 2019-08-06 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US11696908B2 (en) | 2007-01-31 | 2023-07-11 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US9636317B2 (en) | 2007-01-31 | 2017-05-02 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US9974764B2 (en) | 2007-01-31 | 2018-05-22 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| CA2676551C (en) | 2007-01-31 | 2015-12-22 | Biosuccess Biotech Company | Compositions and methods of use of phorbol esters |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US11564901B2 (en) | 2007-01-31 | 2023-01-31 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters |
| CN101195609B (en) * | 2007-09-28 | 2011-04-20 | 武汉远大制药集团有限公司 | Method for producing 5,6-dimethyl xanthenone-4-acetic acid, derivant and pharmaceutical formulation produced with the method |
| CN101878206A (en) * | 2007-10-23 | 2010-11-03 | 安蒂索马研究有限公司 | Crystalline forms of (5, 6-dimethyl-9-oxo-9H-xanthen-4-yl) acetic acid sodium salt |
| KR101770435B1 (en) * | 2008-10-03 | 2017-09-05 | 큐알엔에이, 인크. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoproteina1 |
| EP2370579B1 (en) * | 2008-12-04 | 2017-03-29 | CuRNA, Inc. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
| US8927511B2 (en) * | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
| CN107338251A (en) | 2008-12-04 | 2017-11-10 | 库尔纳公司 | It is diseases related that natural antisense transcript by suppressing tumor suppressor gene treats tumor suppressor gene |
| PL2396038T3 (en) | 2009-02-12 | 2016-05-31 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
| EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| KR101835889B1 (en) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
| ES2618572T3 (en) | 2009-05-08 | 2017-06-21 | Curna, Inc. | Treatment of diseases related to the dystrophin family by inhibiting a natural antisense transcript for the dmd family |
| KR101749356B1 (en) | 2009-05-18 | 2017-07-06 | 큐알엔에이, 인크. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
| CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| CA2764683A1 (en) | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| ES2620960T3 (en) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Treatment of diseases related to a collagen gene by inhibiting a natural antisense transcript to a collagen gene |
| ES2629339T3 (en) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1 |
| KR101807323B1 (en) | 2009-06-24 | 2017-12-08 | 큐알엔에이, 인크. | Ttreatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| KR101807324B1 (en) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| CN102712925B (en) | 2009-07-24 | 2017-10-27 | 库尔纳公司 | Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT) |
| CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
| JP6189594B2 (en) | 2009-08-11 | 2017-08-30 | クルナ・インコーポレーテッド | Treatment of adiponectin (ADIPOQ) -related diseases by suppression of natural antisense transcripts against adiponectin (ADIPOQ) |
| CN102482670B (en) | 2009-08-21 | 2018-06-15 | 库尔纳公司 | Treatment of CHIP-associated diseases by inhibiting the natural antisense transcript of 'C-terminus of HSP70-interacting protein' (CHIP) |
| CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | Treatment of IQGAP-associated diseases by inhibiting the natural antisense transcript of 'IQ motif-containing GTPase-activating protein' (IQGAP) |
| EP2480669B1 (en) | 2009-09-25 | 2017-11-08 | CuRNA, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
| DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
| WO2011079263A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
| WO2011090741A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
| JP5993744B2 (en) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー，インコーポレイテッド | Treatment of nuclear respiratory factor 1 related diseases by inhibition of natural antisense transcripts against nuclear respiratory factor 1 (NRF1) |
| KR101853511B1 (en) | 2009-12-31 | 2018-06-20 | 큐알엔에이, 인크. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| WO2011082409A2 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| JP5963680B2 (en) | 2010-01-06 | 2016-08-03 | カッパーアールエヌエー，インコーポレイテッド | Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes |
| CA2786535C (en) | 2010-01-11 | 2019-03-26 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| ES2671877T3 (en) | 2010-01-25 | 2018-06-11 | Curna, Inc. | Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1 |
| KR101838308B1 (en) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| ES2657969T3 (en) | 2010-04-02 | 2018-03-07 | Curna, Inc. | Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3 |
| JP5978203B2 (en) | 2010-04-09 | 2016-08-24 | カッパーアールエヌエー，インコーポレイテッド | Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21 |
| RU2018110642A (en) | 2010-05-03 | 2019-02-27 | Курна, Инк. | TREATMENT OF DISEASES ASSOCIATED WITH SIRTUIN (SIRT) BY INHIBITING A NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN (SIRT) |
| TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
| WO2011150005A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| ES2664585T3 (en) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Treatment of diseases related to methionine sulfoxide reductase (MSRA) by inhibiting the natural antisense transcript to MSRA |
| CN103025873B (en) | 2010-06-23 | 2018-05-08 | 库尔纳公司 | Treatment of SCNA-associated diseases by inhibiting natural antisense transcripts of voltage-gated sodium channel alpha subunit (SCNA) |
| CN103068982B (en) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG) |
| EP2425830A1 (en) | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| CN103210086B (en) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | Treatment of NEU4-associated diseases by inhibiting the natural antisense transcript of sialidase 4 (NEU4) |
| JP6049623B2 (en) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー，インコーポレイテッド | Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA) |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| EP2643463B1 (en) | 2010-11-23 | 2017-09-27 | CuRNA, Inc. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| ES2653247T3 (en) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene |
| EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| US9550722B2 (en) | 2012-01-18 | 2017-01-24 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbal esters for the treatment of stroke |
| US10099996B2 (en) | 2012-01-18 | 2018-10-16 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| JP2015511494A (en) | 2012-03-15 | 2015-04-20 | キュアナ，インク． | Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF) |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655470A (en) | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| DE2015265A1 (en) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkanoic acids and processes for their preparation |
| FR2516922A1 (en) | 1981-11-25 | 1983-05-27 | Lipha | ACIDS (OXO-4-4H- (1) -BENZOPYRAN-8-YL) ALKANOIC, SALTS AND DERIVATIVES, PREPARATION AND DRUG CONTAINING THEM |
| ATE92499T1 (en) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | TUMOR TREATMENT IN MAMMALS. |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5281620A (en) | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| ES2061518T3 (en) | 1986-12-23 | 1994-12-16 | Warner Lambert Co | COMPOUNDS THAT HAVE ANTITUMORAL AND ANTIBACTERIAL PROPERTIES. |
| JPH01193227A (en) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | Adjuvant for cancer immunotherapy |
| US5126129A (en) | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| EP0551200A1 (en) * | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| GB9308166D0 (en) | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
| GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
| US5620875A (en) | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| WO1996032418A1 (en) * | 1995-04-13 | 1996-10-17 | Laboratoires Om S.A. | Anti-cd14 antibodies for use in the induction of il-10 secretion |
| JPH0912595A (en) * | 1995-04-27 | 1997-01-14 | Takeda Chem Ind Ltd | Tan-2178 or its derivative, production and use of tan-2178 |
| EP0743064A1 (en) | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
| JPH0940690A (en) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | Steroid glycoside and medicine containing the same as active ingredient |
| WO1997004761A1 (en) * | 1995-07-28 | 1997-02-13 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
| US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| JPH1081666A (en) * | 1996-06-12 | 1998-03-31 | Ishihara Sangyo Kaisha Ltd | Phthalimide derivative or salt thereof, its production and medicinal composition containing the same |
| WO1998025616A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for cerebral focal stroke |
| AU5792398A (en) | 1996-12-13 | 1998-07-03 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
| UA47505C2 (en) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | METHOD OF TREATMENT OF PLASTIC CELL CANCER OF THE ORAL CAVITY WITH THE HELP OF LEUKOTRIENE ANTAGONISTS |
| US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
| HUP9904672A2 (en) | 1997-03-21 | 2000-05-28 | Eli Lilly And Co. | Leukotriene antagonists used against squamous cell carcinoma of the oral cavity |
| WO1998042345A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
| AU6764798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
| WO1998042336A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
| US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| AU6450498A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
| DE19721211A1 (en) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Three-fold treatment of tumours providing synergistic effect |
| EP1107784A2 (en) | 1998-08-24 | 2001-06-20 | Maxim Pharmaceuticals, Inc. | Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| ES2234523T3 (en) | 1999-03-01 | 2005-07-01 | Pfizer Products Inc. | OXAMIC ACIDS CONTAINING CIANO AND ITS DERIVATIVES AS LEGANDS OF THYROID RECEPTORS. |
| ATE324888T1 (en) | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | CANCER THERAPY |
| US6806257B1 (en) | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| HK1050132A1 (en) | 1999-11-11 | 2003-06-13 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1231939A2 (en) | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1916501A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| JP2003522790A (en) | 2000-02-17 | 2003-07-29 | メルク エンド カムパニー インコーポレーテッド | Treatment or prevention of prostate cancer using a COX-2 selective inhibitor |
| JP2001247459A (en) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | Cancer combination therapy |
| EP1311262A4 (en) | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | CANCER THERAPY THROUGH COMBINATION THERAPY |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| WO2007023302A1 (en) | 2005-08-26 | 2007-03-01 | Antisoma Plc | Combinations comprising dmxaa for the treatment of cancer |
-
2001
- 2001-07-27 EP EP01961455A patent/EP1311262A4/en not_active Withdrawn
- 2001-07-27 AU AU2001282717A patent/AU2001282717A1/en not_active Abandoned
- 2001-07-27 WO PCT/NZ2001/000154 patent/WO2002009700A1/en not_active Ceased
- 2001-07-27 JP JP2002515253A patent/JP2004505047A/en active Pending
-
2003
- 2003-01-14 US US10/341,736 patent/US7510830B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1311262A1 (en) | 2003-05-21 |
| WO2002009700A1 (en) | 2002-02-07 |
| EP1311262A4 (en) | 2005-06-01 |
| US7510830B2 (en) | 2009-03-31 |
| US20040087611A1 (en) | 2004-05-06 |
| JP2004505047A (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001282717A1 (en) | Cancer treatment by combination therapy | |
| IL251270A0 (en) | Cancer treatment | |
| AU2001294604A1 (en) | Improved radiation therapy treatment method | |
| AUPS054702A0 (en) | Cancer therapy | |
| AU2002223827A1 (en) | Well treatment | |
| AU2002226650A1 (en) | Redox therapy for tumors | |
| HUP0500424A3 (en) | Combination therapy for the treatment of cancer | |
| AUPQ923100A0 (en) | Treatment of prostate cancer | |
| AU2001243515A1 (en) | Combination drug therapy | |
| GB0001710D0 (en) | Therapeutic treatment | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU2002335667A1 (en) | Modified reoviral therapy | |
| AU2002215111A1 (en) | Ruthenium-aryl-compounds in cancer therapy | |
| AU2096002A (en) | Therapeutic treatment | |
| AU3567500A (en) | Photodynamic therapy compounds | |
| GB0026015D0 (en) | Cancer treatment | |
| ZA200203166B (en) | Treatment of cancer. | |
| AU5552400A (en) | Treatment of cancer | |
| AU2002331816A1 (en) | A cancer treatment system | |
| AU2001261324A1 (en) | Psoriasis treatment | |
| AU2002351382A1 (en) | Combination cancer therapy | |
| AU2001289127A1 (en) | Tumor treatment | |
| AU2001257168A1 (en) | Cancer treatment | |
| AU2001292897A1 (en) | Novel therapy | |
| AU4598100A (en) | Treating cancer |